Singapore - English - HSA (Health Sciences Authority)

organon singapore pte. ltd. - amlodipine camsylate 7.84mg eqv to amlodipine; losartan 91.52mg eqv to losartan potassium - tablet, film coated - 5mg - amlodipine camsylate 7.84mg eqv to amlodipine 5mg; losartan 91.52mg eqv to losartan potassium 100.00mg

Singapore - English - HSA (Health Sciences Authority)

organon singapore pte. ltd. - amlodipine camsylate 7.84mg eqv to amlodipine; losartan 45.76mg eqv to losartan potassium - tablet, film coated - 5mg - amlodipine camsylate 7.84mg eqv to amlodipine 5mg; losartan 45.76mg eqv to losartan potassium 50.00mg

United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - losartan potassium 25 mg - losartan potassium tablets, usp are indicated for the treatment of hypertension. they may be used alone or in combination with other antihypertensive agents, including diuretics. losartan potassium tablets, usp are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients. (see  precautions, race  and clinical pharmacology, pharmacodynamics and clinical effects, reduction in the risk of stroke, race .) losartan potassium tablets, usp are indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 diabetes and a history of hypertension. in this population, losartan potassium tablets, usp reduce the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease (nee

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - losartan potassium 25 mg - losartan potassium tablets, usp is indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents, including diuretics. losartan potassium tablets usp is indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients. (see precautions , race and clinical pharmacology , pharmacodynamics and clinical effects, reduction in the risk of stroke, race .) nephropathy in type 2 diabetic patients   losartan potassium is indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥ 300 mg/g) in patients with type 2 diabetes and a history of hypertension. in this population, losartan potassium reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease (need for dialysis or renal transplantation) (se

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th), losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89) - hydrochlorothiazide 25 mg - losartan potassium and hydrochlorothiazide tablets usp are indicated for the treatment of hypertension. this fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients (see clinical pharmacology, pharmacodynamics and clinical effects, and dosage and administration). losartan potassium and hydrochlorothiazide tablets usp are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients. (see precautions, race, clinical pharmacology, pharmacodynamics and clinical effects, losartan potassium, reduction in the risk of stroke, race , and dosage and administration .) losartan and hydrochlorothiazide is contraindicated in patients who are hypersensitive to any component of this product. because of the hydrochlorothia

United States - English - NLM (National Library of Medicine)

sandoz inc. - losartan potassium (unii: 3st302b24a) (losartan - unii:jms50mpo89), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - losartan potassium 50 mg - losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. this fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients (see clinical pharmacology, pharmacodynamics and clinical effects and dosage and administration). losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to black patients. (see precautions, race, clinical pharmacology, pharmacodynamics and clinical effects, losartan potassium, reduction in the risk of stroke, race, and dosage and administration.) losartan potassium and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to any component of this product. because of the hydroch

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - losartan potassium - oral tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - losartan potassium - oral tablet - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

dexcel-pharma ltd - losartan potassium - oral tablet - 100mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - losartan potassium - oral tablet - 100mg